PE20090123A1 - Un derivado heterociclico conteniendo nitrogeno y un farmaco conteniendo el mismo como el ingrediente activo - Google Patents
Un derivado heterociclico conteniendo nitrogeno y un farmaco conteniendo el mismo como el ingrediente activoInfo
- Publication number
- PE20090123A1 PE20090123A1 PE2008001407A PE2008001407A PE20090123A1 PE 20090123 A1 PE20090123 A1 PE 20090123A1 PE 2008001407 A PE2008001407 A PE 2008001407A PE 2008001407 A PE2008001407 A PE 2008001407A PE 20090123 A1 PE20090123 A1 PE 20090123A1
- Authority
- PE
- Peru
- Prior art keywords
- amino
- members
- active ingredient
- same
- methylsulfonil
- Prior art date
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 title 2
- 239000004480 active ingredient Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 229910052757 nitrogen Inorganic materials 0.000 title 1
- -1 BUTYL Chemical class 0.000 abstract 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 abstract 2
- 239000004215 Carbon black (E152) Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229930195733 hydrocarbon Natural products 0.000 abstract 2
- 150000002430 hydrocarbons Chemical class 0.000 abstract 2
- KHUXNRRPPZOJPT-UHFFFAOYSA-N phenoxy radical Chemical compound O=C1C=C[CH]C=C1 KHUXNRRPPZOJPT-UHFFFAOYSA-N 0.000 abstract 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 abstract 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 abstract 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 abstract 1
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- 229940123468 Transferase inhibitor Drugs 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000002604 chemokine receptor CCR2 antagonist Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940125777 fusion inhibitor Drugs 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000003558 transferase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A DERIVADOS HETEROCICLICOS DE FORMULA I, DONDE R1 ES N(R1A)SO2-R1B, -COOR1E, -OR1F, ENTRE OTROS; R1A, R1B, R1E Y R1F SON CADA UNO H, HIDROCARBURO SUSTITUIDO O NO, HETEROCICLO DE 3-15 MIEMBROS, ENTRE OTROS; X E Y SON CADA UNO UN ENLACE O ALQUILO C1-C3; A Y B SON ANILLOS QUE REPRESENTAN CADA UNO CARBOCICLICO DE 3-15 MIEMBROS, HETEROCICLO SUSTITUIDO O NO; D ES UN HETEROCICLO NITROGENADO DE 3-15 MIEMBROS SUSTITUIDO O NO; R2 ES H, HIDROCARBURO SUSTITUIDO O NO, CN, OH, ENTRE OTROS. SON COMPUESTOS PREFERIDOS:2-(5-{[(BUTIL{1-[(6-{4-[(METILSULFONIL)AMINO]FENOXI}-3-PIRIDINIL)METIL]-4-PIPERIDINIL}AMINO)CARBONIL]AMINO}-2,4-DIFLUOROFENIL)ACETAMIDA; N'-(4-FLUOROFENIL)-N-[1-({6-[4-(METILSULFONIL)FENOXI]PIRIDI-3-NIL}METIL)PIPERIDI-4-NIL]-N-FENILUREA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA, LA CUAL PUEDE CONTENER UNO O MAS AGENTES SELECCIONADOS DE UN INHIBIDOR DE TRANSFERASA INVERSA, ANTAGONISTA CCR2, INHIBIDOR DE FUSION, INMUNOSUPRESOR, ENTRE OTROS. DICHOS COMPUESTOS SON ANTAGONISTAS DE QUIMIOCINA CCR5 Y SON UTILES EN LA PREVENCION Y/O TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS, INMUNOLOGICAS, INFECCIOSAS, ALERGICAS, ENTRE OTROS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004264855 | 2004-09-13 | ||
| JP2005127359 | 2005-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090123A1 true PE20090123A1 (es) | 2009-03-10 |
Family
ID=36060170
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005001056A PE20060598A1 (es) | 2004-09-13 | 2005-09-12 | Derivado heterociclo conteniendo nitrogeno como antagonista de quimiocina ccr5 |
| PE2008001407A PE20090123A1 (es) | 2004-09-13 | 2005-09-12 | Un derivado heterociclico conteniendo nitrogeno y un farmaco conteniendo el mismo como el ingrediente activo |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005001056A PE20060598A1 (es) | 2004-09-13 | 2005-09-12 | Derivado heterociclo conteniendo nitrogeno como antagonista de quimiocina ccr5 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US8143404B2 (es) |
| EP (2) | EP2546234A1 (es) |
| JP (1) | JP4894518B2 (es) |
| KR (1) | KR101231466B1 (es) |
| CN (1) | CN101775013A (es) |
| AR (1) | AR050643A1 (es) |
| AU (1) | AU2005283326B2 (es) |
| BR (1) | BRPI0515164A (es) |
| CA (1) | CA2579501C (es) |
| ES (1) | ES2457041T3 (es) |
| IL (1) | IL181783A (es) |
| MA (1) | MA28921B1 (es) |
| MX (1) | MX2007002886A (es) |
| NO (1) | NO20071342L (es) |
| NZ (1) | NZ553696A (es) |
| PE (2) | PE20060598A1 (es) |
| RU (1) | RU2409565C2 (es) |
| SG (1) | SG146673A1 (es) |
| TW (1) | TWI400232B (es) |
| WO (1) | WO2006030925A1 (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2385040A1 (en) | 2003-03-14 | 2011-11-09 | ONO Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient |
| ATE426597T1 (de) * | 2004-02-18 | 2009-04-15 | Astrazeneca Ab | Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel |
| TW200600086A (en) * | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| CA2579501C (en) | 2004-09-13 | 2013-09-10 | Ono Pharmaceutical Co., Ltd. | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient |
| ES2397648T3 (es) * | 2005-07-09 | 2013-03-08 | Astrazeneca Ab | Derivados de heteroarilbenzamida para uso como activadores de GLK en el tratamiento de la diabetes |
| US20070066624A1 (en) * | 2005-08-16 | 2007-03-22 | Anormed, Inc. | Chemokine receptor binding compounds |
| MX2008011414A (es) | 2006-03-10 | 2008-09-22 | Ono Pharmaceutical Co | Derivado heterociclico nitrogenado y agente farmaceutico que comprende el derivado como ingrediente activo. |
| MX2008014672A (es) | 2006-05-19 | 2009-03-09 | Abbott Lab | Derivados de alcano azabiciclico sustituidos con bicicloheterociclo fusionado activos en el sistema nervioso central. |
| TW200813018A (en) | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
| CL2007003061A1 (es) | 2006-10-26 | 2008-08-01 | Astrazeneca Ab | Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2. |
| US10512644B2 (en) | 2007-03-12 | 2019-12-24 | Inheris Pharmaceuticals, Inc. | Oligomer-opioid agonist conjugates |
| US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
| US8119661B2 (en) | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
| WO2009058919A1 (en) * | 2007-10-31 | 2009-05-07 | Smithkline Beecham Corporation | Ccr5 antagonists as therapeutic agents |
| WO2009058921A1 (en) * | 2007-10-31 | 2009-05-07 | Smithkline Beecham Corporation | Ccr5 antagonists as therapeutic agents |
| JO2911B1 (en) | 2008-04-11 | 2015-09-15 | جانسن فارمسيتكا ان في | Thiazoloperidine-2-amoxicillinyl-phenyl and thiazoloperazine-2-amoxicillinyl phenyl amine as agents for the control of leukotrien A4 hydrolase |
| JP5600104B2 (ja) | 2008-08-01 | 2014-10-01 | ベンティアールエックス ファーマシューティカルズ， インコーポレイテッド | Ｔｏｌｌ様受容体アゴニスト処方物およびその使用 |
| WO2010015849A2 (en) | 2008-08-04 | 2010-02-11 | Astrazeneca Ab | Therapeutic agents 414 |
| US20110237614A1 (en) * | 2008-09-16 | 2011-09-29 | Nektar Therapeutics | Pegylated Opioids with Low Potential for Abuse |
| AU2009313392B2 (en) | 2008-11-06 | 2016-05-05 | Array Biopharma, Inc. | Methods of synthesis of benzazepine derivatives |
| NZ593473A (en) | 2009-01-12 | 2013-02-22 | Pfizer Ltd | Sulfonamide derivatives |
| GB0902434D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Chemical process |
| GB0902406D0 (en) | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Crystalline polymorphic form |
| WO2010116177A1 (en) | 2009-04-09 | 2010-10-14 | Astrazeneca Ab | A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity |
| WO2010116176A1 (en) * | 2009-04-09 | 2010-10-14 | Astrazeneca Ab | Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity |
| KR101727650B1 (ko) | 2009-05-14 | 2017-04-17 | 얀센 파마슈티카 엔.브이. | 류코트리엔 ａ4 하이드롤라아제의 조절제로서의 2개의 융합된 바이사이클릭 헤테로아릴 부분을 갖는 화합물 |
| CN102753542B (zh) | 2009-08-18 | 2016-01-20 | 文蒂雷克斯药品公司 | 作为t0ll样受体调节剂的取代的苯并氮杂* |
| HRP20170268T1 (hr) * | 2009-08-18 | 2017-05-19 | Ventirx Pharmaceuticals, Inc. | Supstituirani benzodiazepeni kao modulatori receptora sličnih tollu |
| EP2308484A1 (en) * | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets |
| GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| CA2804173C (en) | 2010-07-09 | 2015-01-13 | Pfizer Limited | Sulfonamide nav1.7 inhibitors |
| UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
| CN104302650B (zh) | 2012-03-13 | 2017-07-18 | 瑞斯比维特有限公司 | 晶体pi3激酶抑制剂 |
| US9227977B2 (en) | 2013-03-15 | 2016-01-05 | Respivert Ltd. | Phosphoinositide 3-kinase inhibitors |
| TW201522341A (zh) | 2013-03-15 | 2015-06-16 | Respivert Ltd | 化合物 |
| KR102217285B1 (ko) * | 2013-05-27 | 2021-02-22 | 에프. 호프만-라 로슈 아게 | 신규한 3,4-다이하이드로-2h-이소퀴놀린-1-온 및 2,3-다이하이드로-이소인돌-1-온 화합물 |
| JO3637B1 (ar) | 2015-04-28 | 2020-08-27 | Janssen Sciences Ireland Uc | مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv |
| TW201932470A (zh) | 2017-11-29 | 2019-08-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 具有抗ｒｓｖ活性之吡唑并嘧啶 |
| CA3087926A1 (en) | 2018-01-31 | 2019-08-08 | Janssen Sciences Ireland Unlimited Company | Cycloalkyl substituted pyrazolopyrimidines having activity against rsv |
| MX2020011200A (es) | 2018-04-23 | 2020-11-13 | Janssen Sciences Ireland Unlimited Co | Compuestos heteroaromaticos que tienen actividad contra vrs. |
| US12365670B2 (en) | 2018-11-22 | 2025-07-22 | Qilu Regor Therapeutics Inc. | GLP-IR agonists and uses thereof |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| EP4603143A3 (en) | 2018-12-28 | 2025-11-05 | Mitsubishi Tanabe Pharma Corporation | Crystal of pyrrolidine compound |
| US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| IL321606A (en) * | 2022-12-28 | 2025-08-01 | Reservoir Neuroscience Inc | EP2 antagonist compounds |
| WO2025034531A1 (en) * | 2023-08-04 | 2025-02-13 | The University Of Vermont And State Agricultural College | Small molecule allosteric modulator to pac1 receptor and uses thereof |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1063744A (en) * | 1964-05-25 | 1967-03-30 | American Cyanamid Co | 4-substituted-4'-tertiary aminoalkoxy biphenyls |
| US5169855A (en) | 1990-03-28 | 1992-12-08 | Du Pont Merck Pharmaceutical Company | Piperidine ether derivatives as psychotropic drugs or plant fungicides |
| US5364865A (en) * | 1992-12-30 | 1994-11-15 | Sterling Winthrop Inc. | Phenoxy- and phenoxyalkyl-piperidines as antiviral agents |
| US5486534A (en) * | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
| US5593994A (en) | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
| IL118469A (en) | 1995-06-15 | 2000-08-13 | Tanabe Seiyaku Co | Naphthalene derivatives their preparation and intermediates thereof |
| EA001437B1 (ru) | 1996-03-28 | 2001-02-26 | Глаксо Груп Лимитед | Производные пирролопирролона в качестве ингибиторов нейтрофильной эластазы |
| WO1998025605A1 (en) | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
| SK82799A3 (en) | 1996-12-19 | 2001-09-11 | Hoechst Marion Roussel Inc | Novel carboxy substituted cyclic carboxamide derivatives |
| ZA985542B (en) * | 1997-07-03 | 1999-04-07 | Smithkline Beecham Corp | Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents |
| EP1003514A4 (en) | 1997-07-25 | 2000-10-11 | Merck & Co Inc | CYCLIC AMINE MODULATORS OF CHEMOKIN RECEPTORS |
| GB9716657D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| US6340759B1 (en) * | 1997-10-02 | 2002-01-22 | Eisai Co., Ltd. | Fused pyridine derivatives |
| AR013669A1 (es) | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
| WO1999031062A1 (en) | 1997-12-17 | 1999-06-24 | Shionogi & Co., Ltd. | Novel pyridine compounds |
| CN1282243A (zh) | 1997-12-19 | 2001-01-31 | 武田药品工业株式会社 | 用于拮抗ccr5的含n－酰苯胺衍生物的药物组合物 |
| JP2002501898A (ja) | 1998-02-02 | 2002-01-22 | メルク エンド カムパニー インコーポレーテッド | ケモカイン受容体活性の環状アミン調節剤 |
| GB9803226D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
| EP1076557A1 (en) | 1998-04-27 | 2001-02-21 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| CA2329821A1 (en) | 1998-04-27 | 1999-11-04 | Dashyant Dhanak | Ccr-3 receptor antagonists |
| JP2002521441A (ja) | 1998-07-28 | 2002-07-16 | スミスクライン・ビーチャム・コーポレイション | Ｃｃｒ５モジュレーターとしてのプロペンアミド |
| WO2000006085A2 (en) | 1998-07-28 | 2000-02-10 | Smithkline Beecham Corporation | Compounds and methods |
| KR20010074779A (ko) | 1998-07-28 | 2001-08-09 | 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 | 치환된 아닐리드 화합물 및 제조방법 |
| US6096780A (en) * | 1998-08-20 | 2000-08-01 | Takeda Chemical Industries, Ltd. | Quaternary ammonium salts and their use |
| WO2000021916A1 (fr) | 1998-10-15 | 2000-04-20 | Takeda Chemical Industries, Ltd. | Procede de preparation de derives d'amine |
| WO2000027843A1 (en) | 1998-11-09 | 2000-05-18 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| WO2000027835A1 (en) | 1998-11-09 | 2000-05-18 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| ATE280157T1 (de) | 1998-11-17 | 2004-11-15 | Hoffmann La Roche | 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii |
| HUP0104364A2 (hu) | 1998-11-20 | 2002-04-29 | F. Hoffmann-La Roche Ag. | Pirrolidinszármazékok, CCR-3 receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények |
| WO2000031033A1 (en) | 1998-11-20 | 2000-06-02 | F. Hoffmann-La Roche Ag | Piperidine ccr-3 receptor antagonists |
| EP1067130A4 (en) | 1998-12-04 | 2004-02-11 | Toray Industries | TRIAZOLO DERIVATIVES, AND CHIMIOKIN INHIBITORS CONTAINING THESE DERIVATIVES AS ACTIVE INGREDIENT |
| WO2000035877A1 (en) | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | Heterocyclic piperidines as modulators of chemokine receptor activity |
| AU770042B2 (en) | 1998-12-18 | 2004-02-12 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| AU2057200A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| WO2000035876A1 (en) | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity |
| CA2347909A1 (en) | 1998-12-18 | 2000-06-22 | Joseph B. Santella, Iii | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| EP1156807A4 (en) | 1998-12-18 | 2002-04-03 | Du Pont Pharm Co | N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS |
| US6492400B1 (en) | 1998-12-18 | 2002-12-10 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| WO2000037455A1 (en) | 1998-12-21 | 2000-06-29 | Takeda Chemical Industries, Ltd. | Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5 |
| US7217714B1 (en) | 1998-12-23 | 2007-05-15 | Agouron Pharmaceuticals, Inc. | CCR5 modulators |
| PE20001420A1 (es) | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
| EP1013276A1 (en) | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
| JP2002534383A (ja) | 1998-12-30 | 2002-10-15 | スミスクライン・ビーチャム・コーポレイション | 化合物および方法 |
| HK1044539A1 (zh) | 1999-01-13 | 2002-10-25 | 千年药品公司 | 作为趋化因子受体调节剂的官能化杂环 |
| WO2000041685A1 (en) | 1999-01-19 | 2000-07-20 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| JP2002535256A (ja) | 1999-01-25 | 2002-10-22 | スミスクライン・ビーチャム・コーポレイション | 化合物および方法 |
| GB9902453D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902452D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902459D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902455D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902461D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| JP2000309598A (ja) | 1999-02-25 | 2000-11-07 | Takeda Chem Ind Ltd | 多剤結合型新規化合物、その製造法および用途 |
| AU3386700A (en) | 1999-03-02 | 2000-09-21 | Merck & Co., Inc. | 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity |
| WO2000051610A1 (en) | 1999-03-02 | 2000-09-08 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| AU3386400A (en) | 1999-03-02 | 2000-09-21 | Merck & Co., Inc. | 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity |
| WO2000051607A1 (en) | 1999-03-02 | 2000-09-08 | Merck & Co., Inc. | 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity |
| WO2000053172A1 (en) | 1999-03-08 | 2000-09-14 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| EP1156801B1 (en) | 1999-03-10 | 2004-07-07 | Smithkline Beecham Corporation | SUBSTITUTED BENZO(1,2-b:5,4-b')DIPYRAN-4-AMINES AS CCR5 MODULATORS |
| AU2942000A (en) | 1999-03-11 | 2000-09-28 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivatives |
| EP1163238B1 (en) | 1999-03-24 | 2006-05-31 | Anormed Inc. | Chemokine recpetor binding heterocyclic compounds |
| US6518286B1 (en) | 1999-03-26 | 2003-02-11 | Astrazeneca Ab | Compounds |
| US6498161B1 (en) | 1999-04-06 | 2002-12-24 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| US6248755B1 (en) | 1999-04-06 | 2001-06-19 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| US6399619B1 (en) | 1999-04-06 | 2002-06-04 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| US6265434B1 (en) | 1999-04-06 | 2001-07-24 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
| CA2371618A1 (en) | 1999-04-28 | 2000-11-09 | Yuji Ishihara | Cyclic amide compounds, their production and use |
| EP1189609A4 (en) | 1999-05-03 | 2002-10-30 | Smithkline Beecham Corp | CXCR-4 RECEPTOR ANTAGONISTS AND THROMBOPOIETIN MIMETIKA |
| IL145741A0 (en) * | 1999-05-04 | 2002-07-25 | Schering Corp | Piperazine derivatives useful as ccrs antagonists |
| MXPA01011116A (es) | 1999-05-04 | 2002-06-04 | Schering Corp | Terapia de hiv de combinacion de antagonista ccr5 - interferon alfa pegilado. |
| AU780983B2 (en) | 1999-05-04 | 2005-04-28 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
| US6391865B1 (en) | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| WO2000068203A1 (en) | 1999-05-07 | 2000-11-16 | Takeda Chemical Industries, Ltd. | Cyclic compounds and uses thereof |
| WO2000069815A1 (en) | 1999-05-13 | 2000-11-23 | Teijin Limited | Ureido-substituted cyclic amine derivatives and their use as drug |
| DK1179341T3 (da) | 1999-05-18 | 2006-03-27 | Teijin Ltd | Lægemidler eller forebyggende midler mod sygdomme der er associeret med chemokiner |
| WO2000073327A1 (en) | 1999-05-27 | 2000-12-07 | Celltek Biotechnologies Inc. | Chemokine receptor ccr3 antagonists |
| US6165261A (en) | 1999-06-10 | 2000-12-26 | Ergon, Inc. | Water-resistant gypsum composition |
| ATE321751T1 (de) | 1999-07-28 | 2006-04-15 | Kirin Brewery | Harnstoffderivate als ccr-3 rezeptor-inhibitoren |
| SE9902987D0 (sv) * | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| US6559160B1 (en) | 1999-08-27 | 2003-05-06 | Chemocentryx, Inc. | Compounds and methods for modulating cxcr3 function |
| FR2798367B1 (fr) * | 1999-09-15 | 2001-11-23 | Valois Sa | Joint de soupape pour valve doseuse |
| ES2233479T3 (es) | 1999-12-03 | 2005-06-16 | Ono Pharmaceutical Co., Ltd. | Derivados de triazaespiro (5,5) undecano y composiciones farmaceuticas que los comprenden, como ingrediente activo. |
| GB0011838D0 (en) | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
| US6894063B2 (en) * | 2000-09-14 | 2005-05-17 | Schering Corporation | Substituted urea neuropeptide Y Y5 Receptor antagonists |
| JP2004509108A (ja) | 2000-09-14 | 2004-03-25 | シェーリング コーポレイション | 置換尿素神経ペプチドｙｙ５受容体アンタゴニスト |
| AR031130A1 (es) | 2000-09-20 | 2003-09-10 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| SK8752003A3 (en) | 2000-12-11 | 2003-11-04 | Tularik Inc | CXCR3 antagonists, pharmaceutical composition comprising same and use thereof |
| GB0100102D0 (en) * | 2001-01-03 | 2001-02-14 | Syngenta Participations Ag | Organic compounds |
| MXPA03008319A (es) | 2001-03-16 | 2003-12-11 | Abbott Lab | Nuevas aminas como ligantes del receptor de histamina-3 y sus aplicaciones terapeuticas. |
| JP3558079B2 (ja) | 2001-03-19 | 2004-08-25 | 小野薬品工業株式会社 | トリアザスピロ［５．５］ウンデカン誘導体およびそれらを有効成分とする薬剤 |
| DE60204951T2 (de) * | 2001-03-29 | 2006-05-11 | Schering Corp. | Ccr5 antagonisten verwendbar für die behandlung von aids |
| GB0108099D0 (en) | 2001-03-30 | 2001-05-23 | Hoffmann La Roche | Aminopiperidine derivatives |
| MXPA03009000A (es) | 2001-04-13 | 2004-02-12 | Boehringer Ingelheim Pharma | Compuestos benzo-fusionados 1,4-disustituidos. |
| US6495569B1 (en) | 2001-04-19 | 2002-12-17 | Millennium Pharmaceuticals, Inc. | Imidazolidine compounds |
| US6469002B1 (en) | 2001-04-19 | 2002-10-22 | Millennium Pharmaceuticals, Inc. | Imidazolidine compounds |
| ATE338035T1 (de) | 2001-06-05 | 2006-09-15 | Boehringer Ingelheim Pharma | 1,4-disubstituierte benzokondensierte cycloalkyl harnstoffverbindungen |
| OA12623A (en) | 2001-06-20 | 2006-06-12 | Pfizer Prod Inc | Novel sulfonic acid derivatives. |
| US6867221B2 (en) * | 2001-08-30 | 2005-03-15 | Kowa Co., Ltd. | Cyclic amine compounds and pharmaceutical composition containing the same |
| AU2002363236A1 (en) | 2001-10-30 | 2003-05-12 | Millennium Pharmaceuticals, Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
| WO2003042174A1 (en) | 2001-11-14 | 2003-05-22 | Schering Corporation | Cannabinoid receptor ligands |
| TW200302717A (en) | 2002-02-06 | 2003-08-16 | Schering Corp | Novel gamma secretase inhibitors |
| GB0203994D0 (en) | 2002-02-20 | 2002-04-03 | Celltech R&D Ltd | Chemical compounds |
| US20030195192A1 (en) * | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| AU2003231872A1 (en) | 2002-06-03 | 2003-12-19 | Smithkline Beecham Corporation | Imidazolium cxcr3 inhibitors |
| US7524852B2 (en) * | 2002-06-07 | 2009-04-28 | Kyowa Hakko Kogyo Co., Ltd. | Bicyclic pyrimidine derivatives |
| TW200413372A (en) | 2002-09-18 | 2004-08-01 | Ono Pharmaceutical Co | Derivatives of triazaspiro [5.5] undecane and medicants using such derivatives as effective ingredient |
| AU2003284984B2 (en) * | 2002-10-30 | 2008-10-23 | Merck Sharp & Dohme Corp. | Gamma-aminoamide modulators of chemokine receptor activity |
| AU2003291403A1 (en) | 2002-11-08 | 2004-06-03 | Neurogen Corporation | 3-substituted-6-aryl pyridined as ligands of c5a receptors |
| WO2004046110A1 (ja) | 2002-11-15 | 2004-06-03 | Yamanouchi Pharmaceutical Co., Ltd. | メラニン凝集ホルモン受容体拮抗剤 |
| JP4666256B2 (ja) * | 2002-12-10 | 2011-04-06 | 小野薬品工業株式会社 | 含窒素複素環化合物およびその医薬用途 |
| JP2004256531A (ja) | 2003-02-07 | 2004-09-16 | Takeda Chem Ind Ltd | 三環性化合物、その製造法および用途 |
| GB0305426D0 (en) | 2003-03-08 | 2003-04-16 | Glaxo Group Ltd | Novel compounds |
| EP2385040A1 (en) * | 2003-03-14 | 2011-11-09 | ONO Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient |
| AU2004233828B2 (en) * | 2003-04-24 | 2009-05-28 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
| EP1661889A4 (en) * | 2003-09-05 | 2009-08-05 | Ono Pharmaceutical Co | ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES |
| CA2579501C (en) | 2004-09-13 | 2013-09-10 | Ono Pharmaceutical Co., Ltd. | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient |
| JP2007063268A (ja) | 2005-08-05 | 2007-03-15 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| US20070066624A1 (en) | 2005-08-16 | 2007-03-22 | Anormed, Inc. | Chemokine receptor binding compounds |
| MX2008011414A (es) * | 2006-03-10 | 2008-09-22 | Ono Pharmaceutical Co | Derivado heterociclico nitrogenado y agente farmaceutico que comprende el derivado como ingrediente activo. |
-
2005
- 2005-09-12 CA CA2579501A patent/CA2579501C/en not_active Expired - Fee Related
- 2005-09-12 AR ARP050103795A patent/AR050643A1/es not_active Application Discontinuation
- 2005-09-12 US US11/662,639 patent/US8143404B2/en not_active Expired - Fee Related
- 2005-09-12 SG SG200807030-2A patent/SG146673A1/en unknown
- 2005-09-12 RU RU2007113814/04A patent/RU2409565C2/ru not_active IP Right Cessation
- 2005-09-12 MX MX2007002886A patent/MX2007002886A/es active IP Right Grant
- 2005-09-12 PE PE2005001056A patent/PE20060598A1/es not_active Application Discontinuation
- 2005-09-12 AU AU2005283326A patent/AU2005283326B2/en not_active Ceased
- 2005-09-12 EP EP12186689A patent/EP2546234A1/en not_active Withdrawn
- 2005-09-12 PE PE2008001407A patent/PE20090123A1/es not_active Application Discontinuation
- 2005-09-12 CN CN201010126265A patent/CN101775013A/zh active Pending
- 2005-09-12 EP EP05785808.6A patent/EP1790637B1/en not_active Expired - Lifetime
- 2005-09-12 WO PCT/JP2005/017209 patent/WO2006030925A1/ja not_active Ceased
- 2005-09-12 ES ES05785808.6T patent/ES2457041T3/es not_active Expired - Lifetime
- 2005-09-12 TW TW094131265A patent/TWI400232B/zh not_active IP Right Cessation
- 2005-09-12 KR KR1020077008318A patent/KR101231466B1/ko not_active Expired - Fee Related
- 2005-09-12 JP JP2006535240A patent/JP4894518B2/ja not_active Expired - Fee Related
- 2005-09-12 NZ NZ553696A patent/NZ553696A/en not_active IP Right Cessation
- 2005-09-12 BR BRPI0515164-3A patent/BRPI0515164A/pt not_active IP Right Cessation
-
2007
- 2007-03-07 IL IL181783A patent/IL181783A/en not_active IP Right Cessation
- 2007-03-12 NO NO20071342A patent/NO20071342L/no not_active Application Discontinuation
- 2007-04-06 MA MA29806A patent/MA28921B1/fr unknown
-
2011
- 2011-01-28 US US13/016,849 patent/US8410276B2/en not_active Expired - Fee Related
-
2012
- 2012-11-21 US US13/682,784 patent/US8604207B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090123A1 (es) | Un derivado heterociclico conteniendo nitrogeno y un farmaco conteniendo el mismo como el ingrediente activo | |
| PE20050874A1 (es) | Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4 | |
| PE20071232A1 (es) | Derivados de piperidina o piperazina como inhibidores de 11-beta hsd1 | |
| RU2437882C2 (ru) | Производные имидазолидинона | |
| PE20090773A1 (es) | Derivados de morfolina pirimidina | |
| PE20051051A1 (es) | Compuestos de triazol como antagonistas de la vasopresina | |
| JP2006500348A5 (es) | ||
| PE20080906A1 (es) | Derivados heteroarilo como inhibidores de citocina | |
| PE20040647A1 (es) | Inhibidores de cinasas de tirosina | |
| NO20063599L (no) | Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
| PE20030007A1 (es) | Inhibidores de aldosa reductasa del grupo de las piridazinonas | |
| PE20090237A1 (es) | Derivados de sulfonamidas como inhibidores de los canales de sodio | |
| KR910009705A (ko) | 수용성이 개선된 이미다조[4,5-b] 퀴놀리닐 옥시알칸산 아미드 | |
| PE20071177A1 (es) | Derivados de 3,5-piridina como inhibidores de renina | |
| PE20091433A1 (es) | Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procedimientos para su preparacion 177 | |
| NO20070555L (no) | Kinazolinonderivater som parp-inhibitorer | |
| PE20050020A1 (es) | DERIVADOS 4-(2-OXO-2,3-DIHIDRO-1-H-IMIDAZO[4,5-b]PIRIDIN-1-IL)-N-(2-OXO-AZEPAN-3-IL)PIPERIDINIL-1-CARBOXAMIDA SUSTITUIDOS COMO ANTAGONISTAS DEL RECEPTOR CGRP | |
| BR0017025A (pt) | Antagonistas do receptor y5 do neuropeptìdeo y de imidazola substituìda | |
| RU2009117469A (ru) | Азотсодержащие гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента | |
| PE20110807A1 (es) | Inhibidores de cinasa akt y p70 s6 | |
| EE200300403A (et) | N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina | |
| PE20090709A1 (es) | Compuestos heterociclico de 5 miembros | |
| AR049696A1 (es) | Derivados de indol | |
| AR057989A1 (es) | Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas | |
| PE20041078A1 (es) | Derivados heterociclicos inhibidores de la elastasa leucocitica humana (elh) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |